Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| BCE | 0.85% | 25.295 | $ | |
| NGG | -0.39% | 87.72 | $ | |
| RIO | 2.04% | 95.36 | $ | |
| BCC | -1.26% | 89.9 | $ | |
| CMSC | 0.21% | 23.56 | $ | |
| JRI | -0.23% | 12.94 | $ | |
| GSK | -1.5% | 59.34 | $ | |
| CMSD | 0.25% | 24.01 | $ | |
| RYCEF | 1.54% | 16.88 | $ | |
| BTI | -2.13% | 61.49 | $ | |
| AZN | -1.3% | 190.555 | $ | |
| BP | 0.26% | 39.11 | $ | |
| RBGPF | 0.12% | 82.5 | $ | |
| VOD | 1.76% | 15.38 | $ | |
| RELX | -0.01% | 29.378 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
L.Sabbadin--IM
